The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond

Oncogene

Volumn 32, Issue 31, 2013, Pages 3569-3576

  Rohwer, N ^a   Zasada, C ^b   Kempa, S ^b   Cramer, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

cancer; DNA damage response; HIF a; hypoxia; metabolism; tumour heterogeneity

Indexed keywords

HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER GROWTH; CARCINOGENESIS; DNA END JOINING REPAIR; DNA REPAIR; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; DNA DAMAGE; DNA REPAIR; GENOMICS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84881235291     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.510     Document Type: Review

References (114)

1. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-634.
2. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011; 12: 9-22.
3. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-1237.
4. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basichelix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
5. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271-273.
6. Hu CJ, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 2007; 18: 4528-4542.
7. Lau KW, Tian YM, Raval RR, Ratcliffe PJ, Pugh CW. Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNAbinding mechanisms. Br J Cancer 2007; 96: 1284-1292.
8. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-554.
9. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003; 278: 11032-11040.
10. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
11. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2: e164.
12. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-56.
13. Weidemann A, Johnson RS. Biology of HIF-1[alpha]. Cell Death Differ 2008; 15: 621-627.
14. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14: 191-201.
15. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
17. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010; 85: 593-598.
18. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335-354.
19. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al. Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
20. Frede S, Berchner-Pfannschmidt U, Fandrey J. Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol 2007; 435: 405-419.
21. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365: 537-547.
22. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
23. Daskalow K, Rohwer N, Raskopf E, Dupuy E, Kuhl A, Loddenkemper C et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med 2010; 88: 817-827.
24. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67: 563-572.
25. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007; 96: 95-103.
26. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM et al. Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. Br J Cancer 2008; 98: 965-973.
27. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-423.
28. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
29. Nilsson H, Jogi A, Beckman S, Harris AL, Poellinger L, Pahlman S. HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 2005; 303: 447-456.
30. Agani FH, Pichiule P, Chavez JC, LaManna JC. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem 2000; 275: 35863-35867.
31. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95: 11715-11720.
32. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 2000; 59: 47-53.
33. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004; 29: 18-24.
34. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
35. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245-2252.
36. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-862.
37. Denekamp J, Dasu A. Inducible repair and the two forms of tumour hypoxia-time for a paradigm shift. Acta Oncol 1999; 38: 903-918.
38. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001; 24: 467-472.
39. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684.
40. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS ONE 2010; 5: e12038.
41. Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 2010; 465: 577-583.
42. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-530.
43. Kallinowski F, Runkel S, Fortmeyer HP, Forster H, Vaupel P. L-glutamine: a major substrate for tumor cells in vivo? J Cancer Res Clin Oncol 1987; 113: 209-215.
44. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009; 8: 41.
45. Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011; 6: e24411.
46. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012; 483: 608-612.
47. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
48. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61: 31-49.
49. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11: 138-148.
50. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
51. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med (Berl) 2007; 85: 139-148.
52. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-192.
53. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979; 52: 650-656.
54. Reinhold HS, Blachiwiecz B, Blok A. Oxygenation and reoxygenation in 'sandwich' tumours. Bibl Anat 1977; 15(Pt 1): 270-272.
55. Yamaura H, Matsuzawa T. Tumor regrowth after irradiation; an experimental approach. Int J Radiat Biol Relat Stud Phys Chem Med 1979; 35: 201-219.
56. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987; 47: 597-601.
57. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marce M, Kumar GK et al. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006; 577(Pt 2): 705-716.
58. Nanduri J, Wang N, Yuan G, Khan SA, Souvannakitti D, Peng YJ et al. Intermittent hypoxia degrades HIF-2alpha via calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities. Proc Natl Acad Sci USA 2009; 106: 1199-1204.
59. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2\+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280: 4321-4328.
60. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-437.
61. Medema RH, Macurek L. Checkpoint control and cancer. Oncogene 2012; 31: 2601-2613.
62. Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15: 6314-6320.
63. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949-1956.
64. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH et al. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem 2006; 281: 13047-13056.
65. van der Groep P, Bouter A, Menko FH, van der WE, van Diest PJ. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 2008; 111: 475-480.
66. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis 2008; 29: 2306-2316.
67. Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell 2010; 40: 509-520.
68. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000; 460: 1-15.
69. Martin-Oliva D, guilar-Quesada R, O'valle F, Munoz-Gamez JA, Martinez-Romero R, Garcia Del MR et al. Inhibition of poly(ADP-ribose) polymerase modulates tumorrelated gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 2006; 66: 5744-5756.
70. Elser M, Borsig L, Hassa PO, Erener S, Messner S, Valovka T et al. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008; 6: 282-290.
71. Martinez-Romero R, Martinez-Lara E, guilar-Quesada R, Peralta A, Oliver FJ, Siles E. PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress. J Cell Biochem 2008; 104: 2248-2260.
72. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
73. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775: 5-20.
74. Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, Kanaya T et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004; 23: 3708-3715.
75. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 2004; 24: 6076-6083.
76. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006; 25: 61-69.
77. Coussens M, Davy P, Brown L, Foster C, Andrews WH, Nagata M et al. RNAi screen for telomerase reverse transcriptase transcriptional regulators identifies HIF1alpha as critical for telomerase function in murine embryonic stem cells. Proc Natl Acad Sci USA 2010; 107: 13842-13847.
78. Wamelink MM, Struys EA, Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J Inherit Metab Dis 2008; 31: 703-717.
79. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 2003; 39: 43-56.
80. Guo S, Miyake M, Liu KJ, Shi H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J Neurochem 2009; 108: 1309-1321.
81. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
82. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011; 13: 1161-1169.
83. Melvin A, Rocha S. Chromatin as an oxygen sensor and active player in the hypoxia response. Cell Signal 2012; 24: 35-43.
84. Wang F, Zhang R, Wu X, Hankinson O. Roles of coactivators in hypoxic induction of the erythropoietin gene. PLoS One 2010; 5: e10002.
85. Xenaki G, Ontikatze T, Rajendran R, Stratford IJ, Dive C, Krstic-Demonacos M et al. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 2008; 27: 5785-5796.
86. Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J 2005; 24: 3846-3858.
87. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006; 25: 1231-1241.
88. Loenarz C, Schofield CJ. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci 2011; 36: 7-18.
89. Sullivan R, Graham CH. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 2009; 8: 1702-1713.
90. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8: 363-369.
91. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14: 435-446.
92. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 2009; 106: 14391-14396.
93. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69: 9056-9064.
94. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR et al. Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. J Oncol 2010; 2010: 757908.
95. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
96. Rundqvist H, Johnson RS. Hypoxia and metastasis in breast cancer. Curr Top Microbiol Immunol 2010; 345: 121-139.
97. Haase VH. Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 2009; 76: 492-499.
98. Brahimi-Horn MC, Bellot G, Pouyssegur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011; 21: 67-72.
99. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010; 16: 5972-5980.
100. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
101. Bertheau P, Cazals-Hatem D, Meignin V, de RA, Verola O, Lesourd A et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998; 51: 370-374.
102. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996; 88: 1054-1059.
103. Losso JN, Bawadi HA. Hypoxia inducible factor pathways as targets for functional foods. J Agric Food Chem 2005; 53: 3751-3768.
104. Calviello G, Di NF, Gragnoli S, Piccioni E, Serini S, Maggiano N et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and-2 and HIF-1alpha induction pathway. Carcinogenesis 2004; 25: 2303-2310.
105. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxiainducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 2003; 9: 3150-3157.
106. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxiainduced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005; 4: 1465-1474.
107. Thomas R, Kim MH. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 2005; 334: 543-548.
108. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007; 72: 395-406.
109. Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 2011; 60: 981-992.
110. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van OE. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975-27981.
111. Liu L, Ning X, Sun L, Shi Y, Han S, Guo C et al. Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem 2007; 303: 151-160.
112. Lienard BM, Conejo-Garcia A, Stolze I, Loenarz C, Oldham NJ, Ratcliffe PJ et al. Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases. Chem Commun (Camb ) 2008; 47: 6393-6395.
113. Zhu XY, Daghini E, Chade AR, Lavi R, Napoli C, Lerman A et al. Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. Life Sci 2008; 83: 801-809.
114. Rohwer N, Lobitz S, Daskalow K, Jons T, Vieth M, Schlag PM et al. HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer 2009; 100: 772-781.